Navigation Links
Heritage Announces $10 Million Financing
Date:4/15/2008

LONDON and EDISON, N.J., April 15 /PRNewswire/ -- Heritage Pharma Ltd. (U.K.) and its wholly owned subsidiary, Heritage Pharmaceuticals Inc. (collectively "Heritage"), announced today the Company has consummated the private placement of Series A Preferred shares lead by Oklahoma City, Oklahoma-based venture capital investors McClendon Venture Company, LLC and TLW Venture Company, LLC for gross proceeds of $10 million prior to fees and expenses. The proceeds will be utilized to finance North America and India product development costs, to establish a research and development facility and for other general corporate purposes.

Commenting on the agreement, Heritage President & CEO, Jeffrey Glazer, stated, "We are very excited to complete this new round of financing. The Company is at a turning point and the infusion of capital will enable us to execute additional global growth strategies that will take Heritage to the next level. Establishment of our own R&D center will provide Heritage with an added level of integration in order to continue growing our generic product pipeline and commercial portfolio. We look forward to adding new product launches this year from our existing portfolio while accelerating our future growth."

About Heritage

Heritage Pharmaceuticals Inc. is a rapidly emerging generic pharmaceutical company engaged in the acquisition, licensing, development, marketing, sale and distribution of generic pharmaceutical products for the global prescription drug markets. Heritage has established itself as a competitor in the generic pharmaceutical industry by initially targeting niche products with revenues that are generally too small to command the resources and attention of major market participants. Heritage launched its U.S. label in 2006 and currently markets 5 products over 17 SKU's, including Ethambutol oral tablets, Hydralazine oral tablets, Hydrochlorothiazide oral tablets, Sulindac oral tablets and Nimodipine soft gel capsules. The Company's business model utilizes strategic outsourcing to U.S.F.D.A. qualified manufacturing and develop organizations in both North America and Asia. The Company will continue to introduce its new generic products during 2008 following its tradition of premier quality, value and service in generics. http://www.heritagepharma.com


'/>"/>
SOURCE Heritage Pharma Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Heritage Victor Valley Medical Group to Host Youth Soccer Clinic
2. UPMC Health Plan and Heritage Valley Health System Combine Resources in LifeSmart, A Community Initiative Designed to Prevent Diabetes
3. Dr. Richard Merkin & Heritage Victor Valley Medical Group to Host Victorville Senior Valentines Day Luncheon
4. Heritage Valley Health System Named a Finalist for Microsoft Healthcare User Group Award
5. Transition of Behavioral Health Services from WPIC-BV to Heritage Valley Health System
6. Heritage and Mission of Serving Children Reflected in Reintroduction of Boys Town Name and Look
7. Kimberly Clark Professional Skin Care Plant Celebrates 30th Anniversary and Strong Heritage of Success in San Antonio
8. In Honor of Hispanic Heritage Month and Spanish Speakers Worldwide International Hyperhidrosis Society Publishes Important New Patient Booklet in Spanish
9. Donate Life America Dispels Myths About Organ & Tissue Donation Among Hispanics During National Hispanic Heritage Month
10. NHP Announces First Quarter Earnings Release Date and Conference Call/Webcast
11. CryoLife Announces Release Date and Teleconference Call Details for First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Ogden Clinic, the largest ... centric payment system, to expand its focus on patient care by providing an ... , “At Ogden Clinic, we are working to become a different type ...
(Date:3/23/2017)... ... March 23, 2017 , ... Vortex Biosciences, provider of circulating ... in circulating tumor cells using microfluidic western blotting” in Nature Communications on March ... technology to capture CTCs and a microfluidic single-CTC resolution Western blot from ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... providing insurance assistance, financial planning, and related services to residents of the region, ... promote awareness of threatened species and wild lands. , Endangered Species International is ...
(Date:3/22/2017)... ... March 22, 2017 , ... Soriant recognizes that ... bypasses that. Healthcare facilities across the country are always forced to focus ... and hospitals, across the country, an efficient and quick way to estimate savings ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... that its digital marketing solutions have enabled Children’s Hospital of The King’s Daughters ... , Recognizing the value of a digital marketing approach, the 206-bed pediatric ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... 23, 2017 ReportsnReports.com adds Global ... research report. The global vagus nerve stimulation market analyst ... focus toward minimally invasive VNS procedures. Few years ago, ... developed countries having high standards of healthcare infrastructure. ... ...
(Date:3/22/2017)... LONDON , March 22, 2017 /PRNewswire/ ... Insight Outlook 2022" report gives comprehensive insight ... growth of global biosimilar insulin market. This ... of insulin molecule, mechanism of insulin in ... of biosimilar insulins along with market overview, ...
(Date:3/22/2017)... , March 22, 2017  ImaginAb Inc. today announced the ... Joseph Limber , chairman of ImaginAb, said "At ... track record that is directly relevant to our business, particularly in ... believe that with his leadership, we can realize our potential." ... Mr. Coombs is a ...
Breaking Medicine Technology: